Edwards Lifesciences (NYSE:EW) Updates FY24 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share guidance of $2.70-2.80 for the period, compared to the consensus earnings per share estimate of $2.75. The company issued revenue guidance of high end of $6.3-3.6 billion, compared to the consensus revenue estimate of $6.52 billion. Edwards Lifesciences also updated its FY 2024 guidance to 2.700-2.800 EPS.

Edwards Lifesciences Stock Down 1.8 %

Shares of Edwards Lifesciences stock traded down $1.58 on Friday, reaching $86.43. The company’s stock had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The company has a market capitalization of $52.02 billion, a price-to-earnings ratio of 37.25, a P/E/G ratio of 4.36 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences has a 52 week low of $60.57 and a 52 week high of $96.12. The firm’s fifty day simple moving average is $90.28 and its two-hundred day simple moving average is $78.85.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. Equities analysts anticipate that Edwards Lifesciences will post 2.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on EW shares. Piper Sandler lifted their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a neutral rating in a research report on Friday. Royal Bank of Canada boosted their price target on Edwards Lifesciences from $95.00 to $101.00 and gave the company an outperform rating in a research note on Monday, April 15th. Mizuho raised their price objective on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a buy rating in a report on Thursday, April 11th. StockNews.com lowered shares of Edwards Lifesciences from a buy rating to a hold rating in a research report on Wednesday, March 20th. Finally, Morgan Stanley increased their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an overweight rating in a research report on Thursday, March 21st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of Moderate Buy and a consensus target price of $93.33.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $94.89, for a total value of $688,426.95. Following the sale, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at $1,809,931.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Heisz Leslie Stone sold 7,056 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total value of $609,991.20. Following the completion of the transaction, the director now directly owns 26,980 shares of the company’s stock, valued at $2,332,421. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the sale, the chief financial officer now directly owns 19,074 shares in the company, valued at approximately $1,809,931.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 194,004 shares of company stock valued at $17,166,254. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.